亚太地区原发性闭角型青光眼市场，按疾病类型（急性闭角型青光眼和慢性闭角型青光眼）、类型（诊断和治疗）、最终用户（医院、专科诊所、门诊手术中心等）、分销渠道（直接招标、零售销售等）、国家（日本、中国、印度、澳大利亚、新加坡、韩国、马来西亚、泰国、印度尼西亚、菲律宾、越南、亚太地区其他地区）划分的行业趋势和预测（至 2028 年）
市场分析与洞察：亚太地区原发性闭角型青光眼市场
原发性闭角型青光眼市场预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场的复合年增长率为 6.1%，预计到 2028 年将达到 3.4082 亿美元。闭角型青光眼患病率的增加和该疾病外科治疗的进步是原发性闭角型青光眼市场发展的主要驱动力。
青光眼是一组损害视神经的眼部疾病，视神经的正常功能是良好视力的必要条件。这种损害通常是由眼压异常高引起的。原发性房角闭合 (PAC) 被定义为前房角的对合或粘连性闭合，在没有青光眼性视神经病变的情况下，这会导致房水流出阻塞和眼压升高。
由于各种解剖和激素因素，女性人口不断增加以及闭角型青光眼患者男女比例增大，表明随着女性人口的增加，该病在女性中的患病率也随之上升，预计这将在预测期内推动原发性闭角型青光眼市场的发展。较低的报销额度被视为原发性闭角型青光眼市场发展的制约因素。产品审批的管理机构在原发性闭角型青光眼市场的增长中发挥着重要作用。预计在预测期内，原发性闭角型青光眼产品审批的不断增加将提振市场发展，并为原发性闭角型青光眼市场的增长带来机遇。微创青光眼手术相关的风险对原发性闭角型青光眼市场来说是一个挑战。
原发性闭角型青光眼市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和原发性闭角型青光眼市场情景，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您创建收入影响解决方案以实现您的预期目标。
原发性闭角型青光眼市场范围和市场规模
原发性闭角型青光眼市场根据疾病类型、类型、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据疾病类型，原发性闭角型青光眼市场分为急性闭角型青光眼和慢性闭角型青光眼。2021 年，由于急性病例发病率高，急性闭角型青光眼细分市场在原发性闭角型青光眼市场中占据主导地位。
- 根据类型，原发性闭角型青光眼市场分为诊断和治疗。2021 年，诊断部分在原发性闭角型青光眼市场中占据主导地位，因为诊断有初级检测和次级检测选项，医生在正确诊断后只会选择医疗程序。
- 根据最终用户，原发性闭角型青光眼市场分为医院、专科诊所、门诊手术中心和其他。2021 年，医院部门在原发性闭角型青光眼市场中占据主导地位，因为该部门专门进行各种外科手术，并拥有大量专业人员可提供适当的治疗。
- 根据分销渠道，原发性闭角型青光眼市场分为直接招标、零售和其他。2021 年，直接招标部分在原发性闭角型青光眼市场中占据主导地位，因为它们是医疗机构和专科诊所采购诊断和手术设备的主要来源。
原发性闭角型青光眼市场国家级分析
对原发性闭角型青光眼市场进行了分析，并按上述国家、疾病类型、类型、最终用户和分销渠道提供了市场规模信息。
亚太原发性闭角型青光眼市场报告涵盖的国家包括日本、中国、印度、澳大利亚、新加坡、韩国、马来西亚、泰国、印度尼西亚、菲律宾、越南和亚太其他地区。
随着生活方式的改变和城市化进程的加快，预计亚太地区将在 2021 年至 2028 年的预测期内以最有希望的增长率增长。日本预计将在亚太地区市场占据主导地位，因为日本是世界上领先的国家之一，其产品使用率和诊断率迅速增长，人们对原发性闭角型青光眼的认识不断提高。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。
新兴市场发病率的不断上升以及从原发性闭角型青光眼药物治疗到手术治疗的快速转变，为原发性闭角型青光眼市场参与者创造了新的机会
原发性闭角型青光眼市场还为您提供每个国家/地区特定行业增长的详细市场分析，包括闭角型青光眼手术和诊断产品销售、原发性闭角型青光眼发展的影响以及监管环境的变化及其对原发性闭角型青光眼市场的支持。数据涵盖 2010 年至 2019 年的历史时期。
竞争格局和原发性闭角型青光眼市场份额分析
原发性闭角型青光眼市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对原发性闭角型青光眼市场的关注有关。
从事原发性闭角型青光眼市场报告的主要公司包括强生视力保健公司（强生服务公司旗下的子公司）、博士伦公司（博士伦医疗公司旗下的子公司）、爱尔康公司、蔡司国际公司、NOVAEYE MEDICAL、NIDEK CO., LTD、Allergan（艾伯维公司旗下的子公司）、APPASAMY ASSOCIATES、Aurolab 等。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。
全球各地的公司还发起了许多产品发布和协议，这也加速了原发性闭角型青光眼市场的发展。
例如，
- 2020 年 6 月，强生视力保健公司宣布向 Optometry Cares – 美国验光协会 (AOA) 基金会和美国验光学会基金会捐款，共计 30 万美元，支持该组织为受 COVID-19 影响的社区提供眼科护理。
市场参与者的合作、合资和其他策略正在增强公司在原发性闭角型青光眼领域的市场，这也为组织改善其在原发性闭角型青光眼市场的供应提供了好处。
可定制：亚太原发性闭角型青光眼市场
Data Bridge Market Research 是高级形成性研究领域的领导者。我们很自豪能够为现有和新客户提供符合其目标的数据和分析。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（Factbook）中的数据，或者可以帮助您根据报告中提供的数据集创建演示文稿。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EPIDEMIOLOGY
5 REGULATORY FRAMEWORK
6 PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA
7.1.2 INCREASING WOMEN POPULATION
7.1.3 RISE IN GERIATRIC POPULATION
7.1.4 ADVANCEMENTS IN SURGICAL TREATMENT OF THE DISEASE
7.1.5 INCREASED ECONOMIC BURDEN
7.2 RESTRAINTS
7.2.1 HIGH SURGICAL COSTS OF PACG
7.2.2 INADEQUATE REIMBURSEMENT SCENARIO
7.2.3 DELAYED AND MISDIAGNOSIS OF PACG
7.3 OPPORTUNITIES
7.3.1 INCREASING GOVERNMENT INITIATIVES TOWARDS GLAUCOMA
7.3.2 RECENT APPROVAL BY GOVERNING BODIES
7.3.3 INCREASING INCIDENCES IN EMERGING MARKET
7.3.4 RAPID TRANSITION FROM PACG MEDICATION TO SURGERIES
7.4 CHALLENGES
7.4.1 RISKS ASSOCIATED WITH SURGICAL PROCEDURES
7.4.2 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE
7.4.3 LIMITED ACCESS TO TREATMENT
8 IMPACT OF COVID-19 ON ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION BY MANUFACTURERS
8.5 CONCLUSION
9 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 ACUTE ANGLE-CLOSURE GLAUCOMA MARKET
9.3 CHRONIC ANGLE-CLOSURE GLAUCOMA MARKET
10 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE
10.1 OVERVIEW
10.2 DIAGNOSIS
10.2.1 PRIMARY TEST
10.2.1.1 GONIOSCOPY EXAMINATION
10.2.1.2 SLIT-LAMP EXAMINATION
10.2.1.3 AUTOMATIC STATIC PERIMETRY
10.2.2 SECONDARY TEST
10.2.2.1 ULTRASOUND BIOMICROSCOPY
10.2.2.2 ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY (OCT)
10.2.2.3 RETINAL OCT
10.2.2.4 FUNDOSCOPY
10.2.2.5 OTHERS
10.3 TREATMENT
10.3.1 SURGICAL IRIDECTOMY
10.3.2 TRABECULECTOMY
10.3.3 MICRO INVASIVE GLAUCOMA TECHNIQUE (MIGS)
10.3.4 GONIOTOMY
10.3.5 OTHERS
11 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 AMBULATORY SURGICAL CENTERS
11.4 SPECIALTY CLINICS
11.5 OTHERS
12 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY GEOGRAPHY
13.1 ASIA-PACIFIC
13.1.1 JAPAN
13.1.2 CHINA
13.1.3 INDIA
13.1.4 AUSTRALIA
13.1.5 SINGAPORE
13.1.6 SOUTH KOREA
13.1.7 MALAYSIA
13.1.8 THAILAND
13.1.9 INDONESIA
13.1.10 PHILIPPINES
13.1.11 VIETNAM
13.1.12 REST OF ASIA-PACIFIC
14 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 SWOT
16 COMPANY PROFILES
16.1 JOHNSON & JOHNSON VISION CARE, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 BAUSCH & LOMB INCORPORATED (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 ALCON INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 ZEISS INTERNATIONAL
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 NOVA EYE MEDICAL LIMITED
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 NIDEK CO., LTD
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 APPASAMY ASSOCIATES
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 AUROLAB
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 BVI
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 LIGHTMED
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 LUNEAU TECHNOLOGY USA
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 MEDISONIC EQUIPMENTS PVT. LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 MICROSURGICAL TECHNOLOGY
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 NEW VISION
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 NEW WORLD MEDICAL, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 OERTLI INSTRUMENTE AG
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 OMNI LENS
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 REICHERT, INC. (A BUSINESS UNIT OF AMETEK.INC.)
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENTS
16.2 SIGHT SCIENCES, INC.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, PIPELINE ANALYSIS
TABLE 2 NUMBER OF OPHTHALMOLOGISTS/MILLION POPULATIONS
TABLE 3 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC ACUTE-ANGLE CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC CHRONIC ANGLE-CLOSURE GLAUCOMA IN PRIMARY ANGLE CLOSURE GLAUCOMA MARKET,BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC HOSPITALS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC AMBULATORY SURGICAL CENTERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC SPECIALTY CLINICS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC DIRECT TENDER IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC RETAIL SALES IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC OTHERS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 31 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 32 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 33 JAPAN DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 34 JAPAN PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 35 JAPAN SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 36 JAPAN TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 37 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 JAPAN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 40 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 41 CHINA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 42 CHINA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 43 CHINA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 44 CHINA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 45 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 CHINA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 47 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 48 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 49 INDIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 50 INDIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 51 INDIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 52 INDIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 53 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 INDIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 56 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 57 AUSTRALIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 58 AUSTRALIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 59 AUSTRALIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 60 AUSTRALIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 61 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 AUSTRALIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 64 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 65 SINGAPORE DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 66 SINGAPORE PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 67 SINGAPORE SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 68 SINGAPORE TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 69 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 SINGAPORE PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 72 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 73 SOUTH KOREA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 74 SOUTH KOREA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 75 SOUTH KOREA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 76 SOUTH KOREA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 77 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 SOUTH KOREA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 79 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 80 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 81 MALAYSIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 82 MALAYSIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 83 MALAYSIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 84 MALAYSIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 85 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 86 MALAYSIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 87 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 88 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 89 THAILAND DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 90 THAILAND PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 91 THAILAND SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 92 THAILAND TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 93 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 THAILAND PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 96 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 97 INDONESIA DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 98 INDONESIA PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 99 INDONESIA SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 100 INDONESIA TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 101 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 102 INDONESIA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 103 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 104 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 105 PHILIPPINES DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 106 PHILIPPINES PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 107 PHILIPPINES SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 108 PHILIPPINES TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 109 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 110 PHILIPPINES PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 111 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET , BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 112 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 113 VIETNAM DIAGNOSIS IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 114 VIETNAM PRIMARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 115 VIETNAM SECONDARY TEST IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 116 VIETNAM TREATMENT IN PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 117 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 118 VIETNAM PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 119 REST OF ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
图片列表
FIGURE 1 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET : DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SEGMENTATION
FIGURE 12 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA AND ADVANCEMENT IN SURGICAL TREATMENT OF THE DISEASE ARE DRIVING THE ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 ACUTE ANGLE-CLOSURE GLAUCOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN 2021 & 2028
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET
FIGURE 16 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020
FIGURE 17 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)
FIGURE 18 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, CAGR (2020-2028)
FIGURE 19 ASIA-PACIFIC PRIMARY ANGLE CLOSURE GLAUCOMA MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020
FIGURE 21 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE 2020-2028 (USD MILLION)
FIGURE 22 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 23 ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020
FIGURE 25 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, 2020-2028 (USD MILLION)
FIGURE 26 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 27 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY END USERS, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 29 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 30 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 31 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY DISTRIBUTION, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: SNAPSHOT (2020)
FIGURE 33 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020)
FIGURE 34 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2021 & 2028)
FIGURE 35 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY COUNTRY (2020 & 2028)
FIGURE 36 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: BY TYPE (2021-2028)
FIGURE 37 ASIA-PACIFIC PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
